BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III SEQUOIA Trial for the Treatment of Chronic Lymphocytic Leukemia

 BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III SEQUOIA Trial for the Treatment of Chronic Lymphocytic Leukemia

BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III SEQUOIA Trial for the Treatment of Chronic Lymphocytic Leukemia

Shots:

  • The P-III SEQUOIA trial evaluating efficacy & safety of Brukinsa vs bendamustine + rituximab (B+R) in patients with treatment-naïve CLL or SLL whose tumor did not exhibit the deletion of chromosome 17p13.1 (del[17p])
  • The interim analysis of trial met its 1EPs @ median follow-up of 25.8 mos, demonstrates improvement in PFS as assessed by IRC. The therapy was well-tolerated & consistent with its known safety profile
  • Brukinsa (zanubrutinib) is a BTK inhibitor, currently being evaluated in multiple clinical studies globally as a monothx. or in combination with other therapies targeting B cell malignancies. The company plans to consult with global regulatory authorities

Click here to read full press release/ article | Ref: BeiGene | Image: BeiGene

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post